Market News AIOpen the app

Cocrystal Pharma shared its third quarter 2026 results, noting it finished dosing for its norovirus study.

ResultsRead the original at globenewswire.com
Neutral

Cocrystal finished dosing the last participant in its norovirus study and reported $435,000 in nine-month revenue and grant income. But efficacy results are pending, and quarterly research costs rose from $954,000 to $1.978 million, leaving no clear change in its outlook.

COCP · Cocrystal Pharma, Inc.

AI read · Neutral

The AI's read

Finishing dosing brings the candidate closer to an efficacy readout, but the report gives no evidence yet that it works. Trial costs also drove research spending higher, so the progress and added costs do not point clearly one way.

Get alerts for COCP

Follow Cocrystal Pharma, Inc. (COCP) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for COCP
Free on the App Store and Google Play, or on the web.